See the DrugPatentWatch profile for Reopro
What is ReoPro (abciximab)?
ReoPro is the brand name for abciximab, an intravenous medicine that blocks the platelet receptor GP IIb/IIIa. By inhibiting this receptor, it helps prevent platelets from clumping and forming blood clots. ReoPro is used in certain high-risk heart situations, typically around procedures such as percutaneous coronary intervention (PCI)/stent placement. [1]
What is ReoPro used for in heart patients?
ReoPro is used to reduce the risk of ischemic complications from clot formation during and after certain cardiac interventions where platelet activity is expected to be high. It is most closely associated with use in the setting of coronary angioplasty/PCI. [1]
How is ReoPro given?
ReoPro is administered by intravenous infusion under medical supervision. The exact dosing regimen depends on the specific clinical situation and protocol used at the treating hospital. [1]
What are common side effects and key risks?
Because ReoPro affects platelet function, the most important risk is bleeding. Other adverse effects can occur, but bleeding is the major concern clinicians monitor closely during treatment. [1]
How does ReoPro compare with other GP IIb/IIIa inhibitors?
ReoPro (abciximab) is one member of the GP IIb/IIIa inhibitor class. Other agents in this class include eptifibatide and tirofiban; differences among them involve factors like binding characteristics, dosing schedules, and clinical protocols. If you tell me which comparison you’re interested in (e.g., “ReoPro vs eptifibatide”), I can narrow it. [1]
Is ReoPro still available and is it used today?
ReoPro remains a known therapy within cardiology practice and is described in drug references, but whether it is used routinely can vary by country, hospital protocol, and how other antiplatelet strategies are being used in modern practice. [1]
Sources
[1] https://www.drugs.com/reopro.html